The Incidence of Guillain Barre Syndrome in the United Kingdom

Aug-09

AUTHORS : Alena Khromava, Epidemiology and Benefit Risk, Sanofi Pasteur, 1755 Steeles AvenueWest, North York, Ontario M2R 3T4, Canada – Email: Alena.Khromava@sanofi.com

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 18(S1):48

DOI : 10.1002/pds.1806

The Incidence of Guillain Barre Syndrome in the United Kingdom

More publications

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality

Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study